Treatment Information

Back

Colon Cancer treatment details. Chemotherapy, Biologic therapy.

Martin Luther University Halle-Wittenberg, Halle, Germany.

Survival: monthsCountry:Germany
Toxiciy Grade:5City/State/Province:Halle
Treatments:Chemotherapy, Biologic therapyHospital:Martin Luther University Halle-Wittenberg
Drugs:Journal:Link
Date:Oct 2012

Description:

Patients:
This phase 3 study involved untreated metastatic colorectal cancer patients who were divided into two separate treatment groups. Group A consisted of 709 patients with a median age of 59 years and 58% male. Group B had 713 patients with a median age of 60 years and 58% male.

Treatment:
Patients in group A were treated with a combination of the chemotherapy agents oxaliplatin, leucovorin, and fluorouracil, as well as the biologic therapy agent cediranib, a tyrosine kinase inhibitor that interferes with tumor growth.

Patients in group A were treated with a combination of the chemotherapy agents oxaliplatin, leucovorin, and fluorouracil, as well as the biologic therapy agent bevacizumab.

Toxicities:
Treatment-related deaths due to unspecified causes were reported for 2.7% of the patients in group A. Grade 3/4 diarrhea, neutropenia, and nerve disorders were also reported.

Treatment-related deaths due to unspecified causes were reported for 3.1% of the patients in group B. Grade 3/4 diarrhea, neutropenia, and nerve disorders were also reported.

Results:
The median overall survival rates for groups A and B were 22.8 and 21.3 months, respectively.

Support:
This study was supported by AstraZeneca, makers of cediranib.

Correspondence: Dr. Hans Joachim Schmoll; email: [email protected]



Back